Design efficiency in dose finding studies

被引:36
作者
Paoletti, X
O'Quigley, J
Maccario, J
机构
[1] INSERM, UNite 436, F-75013 Paris, France
[2] Inst Curie, Biostat Unit, F-75005 Paris, France
[3] INSERM, Unite 472, F-94807 Villejuif, France
基金
美国国家卫生研究院;
关键词
clinical trials; dose finding; efficiency; optimality; phase I designs;
D O I
10.1016/S0167-9473(02)00323-7
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
An investigator about to undertake a dose finding study can choose from rival methods. In selecting any method he or she may have certain properties in mind. Our purpose here is to present an approach to evaluating rival methods which can help provide guidance to the investigator. The idea is to determine which of any given number of competing dose finding studies has a superior performance in given circumstances. The approach is centered around three components. The first of these is simply a very broad class of potential dose-toxicity relations, of which current examples in the literature can be seen to be special cases. The second component, for some given situation or class of situations, is an optimal method, not one that we can necessarily apply in practice, but one that provides a gold standard, beyond which improvements are not generally possible. The third component is a class of efficiency measures which indicate how close to the optimal method is the performance of any given method. We are then able to compare rival approaches both in a relative and absolute sense. (C) 2002 Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 214
页数:18
相关论文
共 22 条
[1]  
[Anonymous], INT J PHARM MED
[2]  
Babb J, 1998, STAT MED, V17, P1103, DOI 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO
[3]  
2-9
[4]   The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes [J].
Braun, TA .
CONTROLLED CLINICAL TRIALS, 2002, 23 (03) :240-256
[5]  
Durham S. D., 1994, STAT DECISION THEORY, VV, P467
[6]  
Faries D, 1994, J Biopharm Stat, V4, P147, DOI 10.1080/10543409408835079
[7]   A curve-free method for Phase I clinical trials [J].
Gasparini, M ;
Eisele, J .
BIOMETRICS, 2000, 56 (02) :609-615
[8]   SOME PRACTICAL IMPROVEMENTS IN THE CONTINUAL REASSESSMENT METHOD FOR PHASE-I STUDIES [J].
GOODMAN, SN ;
ZAHURAK, ML ;
PIANTADOSI, S .
STATISTICS IN MEDICINE, 1995, 14 (11) :1149-1161
[9]   SIMULATION AS A DESIGN TOOL FOR PHASE I/II CLINICAL-TRIALS - AN EXAMPLE FROM BONE-MARROW TRANSPLANTATION [J].
GOOLEY, TA ;
MARTIN, PJ ;
FISHER, LD ;
PETTINGER, M .
CONTROLLED CLINICAL TRIALS, 1994, 15 (06) :450-462
[10]   Longitudinal design for phase I clinical trials using the continual reassessment method [J].
Legedza, ATR ;
Ibrahim, JG .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :574-588